【摘要】 目的观察热毒宁注射液联合头孢哌酮钠舒巴坦钠注射剂治疗慢性阻塞性肺疾病(COPD)合并肺部感染的临床疗效和安全性。方法将68例COPD合并肺部感染患者随机分为对照组34例与试验组34例。对照组给予静脉滴注盐酸莫西沙星氯化钠注射液250 m L,qd,注射用头孢哌酮钠舒巴坦钠静脉滴注1.0g,bid;试验组在对照组治疗的基础上,给予静脉滴注热毒宁注射液20 m L,qd。2组患者均治疗10 d。比较2组患者的临床疗效和药物不良反应发生情况。结果治疗后,试验组和对照组总有效率分别为94.12%(32/34例)和70.59%(24/32例),差异有统计学意义(P<0.05)。试验组出现的主要药物不良反应类型为头痛、胃肠道反应、皮疹,对照组出现的主要药物不良反应类型为头痛、肝酶轻度上升、胃肠道反应、皮疹,试验组和对照组的药物不良反应发生率分别为8.82%和14.71%,差异无统计学意义(P>0.05)。结论热毒宁注射液联合头孢哌酮钠舒巴坦钠注射剂治疗COPD的临床疗效显著,安全性高。更多还原

【Abstract】 Objective To evaluate the efficacy and safety profile of Reduning injection combined with cefoperazone sodium and sulbactam sodium injection in the treatment of pulmonary infection in patients with chronic obstructive pulmonary disease( COPD). Methods A total of 68 patients with COPD were divided into control group( 34 cases) and treatment group( 34 cases). Both groups were given routine treatment.The control group was given moxifloxacin hydrochloride sodium chloride injection 250 m L,intravenous drip, qd; cefoperazone sodium and sulbactam sodium 1. 0 g,intravenous drip,bid. The treatment group received Reduning injection 20 m L,intravenous drip,qd. Both groups were treated for 10 days. The clinical efficacy and adverse drug reactions were compared between the two groups. Results After treatment,the total effective rates of the treatment group and the control group were respectively 94. 12%( 32/34 cases),70. 59%( 24/32 cases), the difference was statistically significant( P < 0. 05). The main adverse drug reactions of treatment group were headache,gastrointestinal reaction and rash,while those of the control group were headache,slight increase of liver enzymes,gastrointestinal reaction and rash,and the incidences of adversedrug reaction were 8. 82%( 3/34 cases) and 14. 71%( 5/34 cases) respectively,without statistically significant difference( P > 0. 05). Conclusion Reduning injection combined with cefoperazone sodium and sulbactam sodium injection in the treatment of COPD was effective with a favourable safety profile.更多还原